Gallus Biopharmaceuticals has signed a multi-year development and manufacturing supply agreement with Sanofi unit Genzyme to provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy targeting Niemann-Pick type B.   “Gallus is delighted to partner with Genzyme in bringing this therapy to patients in need,” said Mark Bamforth, Gallus’ chief executive officer and president. “We are confident that our deep pro...